| Sep 6 |
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
|
| Sep 5 |
Novartis licenses gene therapy component from Voyager
|
| Sep 5 |
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
|
| Aug 29 |
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
|
| Aug 26 |
Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects
|
| Aug 26 |
Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
|
| Aug 8 |
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
|
| Aug 8 |
Voyager Therapeutics, Inc. (VYGR) Q2 2024 Earnings Call Transcript
|
| Aug 7 |
Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
|
| Aug 6 |
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
|
